SNNA - Sienna Biopharmaceuticals And SNA-120 Pegcantratinib In Psoriasis
The Technology Platform
Sienna (SNNA) is a small-cap ($23.97M) pharmaceutical that was publicly listed in 2017. Its scientific forte is the clinical development of tissue–targeted kinase inhibitors (TTKI.) to treat diverse chronic inflammatory and immunologic ailments. The technology platform can be described as a polymer–drug conjugate therapeutics. Sienna explains:
By stably linking a short polyethylene glycol (PEG.) polymer to a pharmacologically active molecule, our technology platform alters the mechanism of action of the starting pharmaceutical ingredient and refines its target selectivity, enabling highly localized drug concentration in various target tissues, while dramatically